por Gus Iversen
, Editor in Chief | April 01, 2015
European patients receiving at home peritoneal dialysis — a common treatment for end-stage renal disease patients — have a new option for receiving the therapy.
Baxter announced today the the completion of CE marking approval for an automated peritoneal dialysis (APD) system that integrates with the company's web-based treatment monitoring platform, SHARESOURCE.
By utilizing secure two-way connectivity, The HOMECHOICE CLARIA APD system allows providers to access timely and personalized data on patients' home peritoneal dialysis (PD) therapies and make adjustments to the prescriptions as needed. It was designed for ease-of-use with a large, two-line display screen and a universal interface that can be programmed in 41 different languages.
The right combination of workflow, clinical equipment and technology can improve patient care, clinical outcomes and your bottom line. Click above to learn more.
"CLARIA builds upon our market-leading HOMECHOICE APD device with new features to make the system more intuitive for patients to operate in their home and while traveling," said Dr. Bruce Culleton, VP of renal therapeutic area lead for Baxter, in a statement.
Together, the device and platform are designed to save clinics time and correct inefficiencies by reducing manual input of data and gathering both patient and clinic data into reports that are organized and easily viewed by providers.
Baxter plans to initiate the commercial launch of the APD system in select European and Asian countries within the coming months.